JWH-007 is an analgesic chemical from the naphthoylindole family, which acts as a cannabinoid agonist at both the CB<sub>1</sub> and CB<sub>2</sub> receptors. It was first reported in 1994 by a group including the noted cannabinoid chemist John W. Huffman. It was the most active of the first group of N-alkyl naphoylindoles discovered by the team led by John W Huffman, several years after the family was initially described with the discovery of the N-morpholinylethyl compounds pravadoline (WIN 48,098), JWH-200 (WIN 55,225) and WIN 55,212-2 by the Sterling Winthrop group. Several other N-alkyl substituents were found to be active by Huffman's team including the n-butyl, n-hexyl, 2-heptyl, and cyclohexylethyl groups, but it was subsequently determined that the 2-methyl group on the indole ring is not required for CB<sub>1</sub> binding, and tends to increase affinity for CB<sub>2</sub> instead. Consequently, the 2-desmethyl derivative of JWH-007, JWH-018, has slightly higher binding affinity for CB<sub>1</sub>, with an optimum binding of 9.00 nM at CB<sub>1</sub> and 2.94 nM at CB<sub>2</sub>, and JWH-007 displayed optimum binding of 9.50 nM at CB<sub>1</sub> and 2.94 nM at CB<sub>2</sub>.
In the United States, all CB<sub>1</sub> receptor agonists of the 3-(1-naphthoyl)indole class such as JWH-007 are Schedule I Controlled Substances.
JWH-007 was banned in Sweden on 1 October 2010 after being identified as an ingredient in "herbal" synthetic cannabis products.
JWH-007 has been illegal in Poland since August 2010.
As of October 2015 JWH-007 is a controlled substance in China.
JWH-007 has been classified under the German BtMG as Anlage II.